The U.S. Food and Drug Administration (FDA) approved tucatinib (Tukysa, Seagen Inc., a subsidiary of Pfizer) on October 7, ...

Following WCLC 2026, Katherine Kuhns details how perioperative immunotherapy, AI patient tools, and wearables are ...

An FDA advisory panel voted to approve GRAIL's Galleri multi-cancer early detection test for adults 50+. Read key oncology ...

At ASTRO 2026, Dr. Erica Braschi Jordan details toxicity tracking, physical therapy referral, and quality of life in proton ...

Patients with prostate cancer can receive radiation after prostatectomy in 25 treatments over 5 weeks instead of 37 treatments over 7 weeks. Long-term data from the NRG-GU003 tria ...

NP Theresa Stukus and NP Nelli Zafman discuss long-term management considerations for a patient with metastatic ...

Oncology clinicians gathered to review relapsed CLL care options, CAR T-cell trial updates, and advanced practice provider roles. On Sept. 28, 2026, oncology healthcare professionals convened at the ...

The U.S. Food and Drug Administration (FDA) has expanded the approved indication for pirtobrutinib (Jaypirca) to include the ...

September marks Gynecologic Cancer Awareness Month, an annual observation focused on increasing public and clinical awareness of gynecologic malignancies, including ovarian, endometrial, cervical, ...

Dr. Wendy Harpham reflects on her journey as a physician and patient, emphasizing precise clinical communication in oncology care. In oncology care, advanced practice providers and bedside nurses ...

FDA approves belzutifan with lenvatinib for advanced clear cell RCC after PD-1/PD-L1 inhibitor failure. Review LITESPARK-011 ...

APHON 2026 speaker Amy C. Haskamp, CNS, discusses tiered self-care tactics and boundaries to help pediatric oncology nurses navigate emotional distress and burnout.